This Article Full Text Full Text (PDF) All Versions of this Article: 38/12/3198    most recent STROKEAHA.107.493106v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Amarenco, P. Search for Related Content PubMed PubMed Citation Articles by Amarenco, P. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Transient Ischemic Attack Related Collections Secondary prevention

(Stroke. 2007;38:3198.)
© 2007 American Heart Association, Inc.

Original Contributions

Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial

Pierre Amarenco, MD; Larry B. Goldstein, MD; Michael Szarek, MS; Henrik Sillesen, MD, MSc; Amy E. Rudolph, PhD; Alfred Callahan, III, MD; Michael Hennerici, MD, PhD; Lisa Simunovic, MS; Justin A. Zivin, MD, PhD; K. Michael A. Welch, MBChB, FRCP on behalf of the SPARCL Investigators

From the Department of Neurology and Stroke Centre, Bichat University Hospital, Denis Diderot University and Medical School, Paris, France.

Correspondence to Pierre Amarenco, MD, Department of Neurology and Stroke Centre, Bichat University Hospital, Denis Diderot University and Medical School, 46, rue Henri Huchard, 75018, Paris, France. E-mail amarenco{at}ccr.jussieu.fr

Background and Purpose— The intention-to-treat analysis of data from the placebo-controlled Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial found 80 mg atorvastatin per day reduced the risk of stroke and major coronary events in patients with recent stroke or transient ischemic attack. This benefit was present despite only a 78% net difference in adherence to randomized treatment over the course of the trial. In this exploratory analysis, our aim was to evaluate the benefit and risks associated with achieving a 50% low-density lipoprotein cholesterol (LDL-C) reduction from baseline.

Methods— This post hoc analysis was based on 55 045 LDL-C measurements among the 4731 patients enrolled in SPARCL (average, 11.6 measurements per patient) during a mean follow-up of 4.9 years. At each postrandomization LDL-C assessment, percent change in LDL-C from baseline for each patient was classified as no change or increase from baseline (32.7% of measurements), <50% LDL-C reduction (39.4%), or 50% reduction (27.9%).

Results— Compared with no change or an increase in LDL-C, analysis of time-varying LDL-C change showed that patients with 50% LDL-C reduction had a 31% reduction in stroke risk (hazard ratio, 0.69, 95% CI, 0.55 to 0.87, P=0.0016), a 33% reduction in ischemic stroke (P=0.0018), no statistically significant increase in hemorrhagic stroke (P=0.8864), and a 37% reduction in major coronary events (P=0.0323). There was no increase in the incidence of myalgia or rhabdomyolysis. Persistent liver enzyme elevations were more frequent in the group with 50% LDL-C reduction.

Conclusions— As compared with having no change or an increase in LDL-C, achieving a 50% lowering was associated with a greater reduction in the risk of stroke and major coronary events with no increase in brain hemorrhages.

Key Words: lipids • prevention • statins • stroke

This article has been cited by other articles:

				D Fiorella, T N Turan, C P Derdeyn, and M I Chimowitz Current status of the management of symptomatic intracranial atherosclerotic disease: the rationale for a randomized trial of medical therapy and intracranial stenting JNIS, July 3, 2009; (2009) jnis.2009.000125v1. [Abstract] [Full Text] [PDF]

				Z. L. S. Brookes, C. C. McGown, and C. S. Reilly Statins for all: the new premed? Br. J. Anaesth., July 1, 2009; 103(1): 99 - 107. [Abstract] [Full Text] [PDF]

				P. Amarenco, L. B. Goldstein, M. Messig, B. J. O'Neill, A. Callahan III, H. Sillesen, M. G. Hennerici, J. A. Zivin, K.M.A. Welch, and on behalf of the SPARCL Investigators Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial Stroke, July 1, 2009; 40(7): 2486 - 2492. [Abstract] [Full Text] [PDF]

				L. B. Goldstein The Complex Relationship Between Cholesterol and Brain Hemorrhage Circulation, April 28, 2009; 119(16): 2131 - 2133. [Full Text] [PDF]

				P. Amarenco, O. Benavente, L. B. Goldstein, A. Callahan III, H. Sillesen, M. G. Hennerici, S. Gilbert, A. E. Rudolph, L. Simunovic, J. A. Zivin, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes Stroke, April 1, 2009; 40(4): 1405 - 1409. [Abstract] [Full Text] [PDF]

				T. N Fitzgerald, C. Popp, A. Dardik, and D. G Federman Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy Vascular Medicine, February 1, 2009; 14(1): 21 - 27. [Abstract] [PDF]

				H. Sillesen, P. Amarenco, M. G. Hennerici, A. Callahan, L. B. Goldstein, J. Zivin, M. Messig, K. M. Welch, and on Behalf of the SPARCL Investigators Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis: A Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial Stroke, December 1, 2008; 39(12): 3297 - 3302. [Abstract] [Full Text] [PDF]

				L. B. Goldstein Response to Letter by Mascitelli et al Stroke, November 1, 2008; 39(11): e181 - e181. [Full Text] [PDF]

				L. R. Caplan A 70-Year-Old Man With a Transient Ischemic Attack: Review of Internal Carotid Artery Stenosis JAMA, July 2, 2008; 300(1): 81 - 90. [Abstract] [Full Text] [PDF]